While small-molecule ALK inhibitors that target the intracytoplasmic kinase domain by binding to the ATP-binding site have been extensively studied and used for cancer treatment, their repurposing for other pathologies, such as neurological, cardiac, and metabolic diseases, has proven challenging [2,3,4]. This evidence concerns the gene ALK and cancer.